Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Posted on January 8th, 2016 by Christy J. WilsonPharma R&D
In early December, the New York Pharma Forum held its 26th Annual General Assembly, focusing on the theme “The Reinvention of Pharma,” and featuring executive-level speakers from Pfizer, Sunovion, Takeda, The Japan Pharmaceutical Manufacturers Association and the consulting company Defined Health to expound upon this theme. Continue reading “Could a Change in R&D Focus Lead to a Reinvented Pharma?” »
Posted on January 7th, 2016 by Neal KatzPharmacovigilance
In December, Elsevier sponsored the 11th Annual Pharmacovigilance, Drug Safety and Risk Management conference in Brussels, Belgium and the 2nd Adverse Event Reporting and Safety Strategies Summit in Philadelphia, USA. Continue reading “Pharmacovigilance events in different regions cover common concerns” »
Posted on January 5th, 2016 by Joanna AldredChemistry
The best present I ever received as a child was a game called Mousetrap. For those unlucky enough not to have played this: releasing a lever leads to a series of seemingly random events, such as a boot kicking a ball, and finally to Continue reading “Proteins behaving badly” »
Posted on December 18th, 2015 by Neal KatzPharma R&D
Technological advances in the retrieval and assessment of pathway and bioactivity data are giving rise to new in silico profiling and modeling methods. Continue reading “A New Approach to Drug Analytics” »
Posted on December 16th, 2015 by Joyce de LangenPharmacovigilance
Limitations of clinical trials and traditional post-marketing sources of safety information.
Due to limitations of pre-marketing clinical trials, there isn’t much information available once a medicinal product is authorized for marketing. Continue reading “Social Media Screening for ADR-monitoring – Like it or not!” »
Posted on December 16th, 2015 by James DunstanPharmacovigilance
At the beginning of September 2015, the EMA launched the Medical Literature Monitoring (MLM) service. I recently read the EMA’s MLM launch phase closure report in addition to information from a recent EMA information day and have highlighted some key points below. Continue reading “Are we expecting too much from the EMA’s MLM service?” »
About this Blog
The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.
Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier, its affiliates and sponsors or its parent company, Reed Elsevier.